Status:
COMPLETED
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second le...
Eligibility Criteria
Inclusion
- Patient must have a history of breast cancer.
- Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.
- Patient must be willing to undergo a duct lavage.
- Patient must sign an Informed Consent.
Exclusion
- None.
Key Trial Info
Start Date :
November 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01207635
Start Date
November 1 2002
End Date
January 1 2006
Last Update
July 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030